Abstract | OBJECTIVE: Owing to advances in transplant science, increasing numbers of patients are receiving solid organ transplantation. New onset diabetes after transplantation (NODAT) frequently develops in transplant patients and requires acute and often ongoing management of hyperglycemia. The metabolic derangements of NODAT are similar to those of classic type 2 diabetes, and treatment has typically followed diabetes standards of care. Best practices for NODAT management remain to be developed. METHODS: The mechanistic suitability of incretins to treat NODAT pathogenesis has been hitherto underappreciated. This review details the specific mechanistic value of incretins in patients with immunosuppression-associated hyperglycemia. RESULTS: CONCLUSION:
|
Authors | Archana R Sadhu, Stanley S Schwartz, Mary E Herman |
Journal | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
(Endocr Pract)
Vol. 21
Issue 7
Pg. 814-22
(Jul 2015)
ISSN: 1530-891X [Print] United States |
PMID | 25786557
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Diabetes Mellitus, Type 2
(drug therapy, etiology)
- Humans
- Incretins
(pharmacology)
- Organ Transplantation
(adverse effects)
|